Mipi b biological Calculator: Free oncology Risk Score & Interpretation

MIPI-bBiological Mantle Cell Lymphoma Prognostic Index

Clinical Risk Band

Assign MIPI-b Category

Note: MIPI-b is calculated by combining age, ECOG performance status, LDH, and white blood cell count (MIPI) with the Ki-67 proliferation index from biopsy pathology.

Awaiting Lab Data

The MIPI-b is the preferred prognostic tool for Mantle Cell Lymphoma (MCL), incorporating both clinical and biological data.

MIPI Factors

Age
ECOG Status
LDH Ratio
WBC Count
Ki-67 Index

Guidelines & Evidence

Verified

Last Review: 2026

When to Use

Newly diagnosed Mantle Cell Lymphoma (MCL).

To risk-stratify patients and determine the aggressiveness of the clinical course.

To inform the discussion surrounding intensive chemoimmunotherapy (e.g., intensive Cytarabine regimens) and upfront autologous stem cell transplantation (ASCT).

How it Works

Variables (Standard MIPI)

Variable	Points/Weighting
Age	Continuous, heavily weighted. >60 increases risk.
ECOG Performance Status	0-1 vs. 2-4
LDH	Ratio to the upper limit of normal.
White Blood Cell Count	Continuous, elevated WBC correlates with leukemic phase and worse outcomes.

The Ki-67 Biological Modifier (MIPI-b)

The Ki-67 proliferation index is assessed via immunohistochemistry. A threshold of ≥ 30% is established as the cutoff for highly proliferative disease. This biological marker acts independently of the clinical variables.

Last Comprehensive Review: 2026

MIPI-bBiological Mantle Cell Lymphoma Prognostic Index

Clinical Risk Band

Assign MIPI-b Category

Note: MIPI-b is calculated by combining age, ECOG performance status, LDH, and white blood cell count (MIPI) with the Ki-67 proliferation index from biopsy pathology.

Awaiting Lab Data

The MIPI-b is the preferred prognostic tool for Mantle Cell Lymphoma (MCL), incorporating both clinical and biological data.

MIPI Factors

Age
ECOG Status
LDH Ratio
WBC Count
Ki-67 Index

Guidelines & Evidence

Verified

Last Review: 2026

When to Use

Newly diagnosed Mantle Cell Lymphoma (MCL).

To risk-stratify patients and determine the aggressiveness of the clinical course.

To inform the discussion surrounding intensive chemoimmunotherapy (e.g., intensive Cytarabine regimens) and upfront autologous stem cell transplantation (ASCT).

How it Works

Variables (Standard MIPI)

Variable	Points/Weighting
Age	Continuous, heavily weighted. >60 increases risk.
ECOG Performance Status	0-1 vs. 2-4
LDH	Ratio to the upper limit of normal.
White Blood Cell Count	Continuous, elevated WBC correlates with leukemic phase and worse outcomes.

The Ki-67 Biological Modifier (MIPI-b)

Last Comprehensive Review: 2026

MIPI-b (Biological)

Clinical Risk Band

When to Use

When to Use

How it Works

Variables (Standard MIPI)

The Ki-67 Biological Modifier (MIPI-b)

Clinical Pearls

Clinical Implications

The Evidence

Key Reference

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

Prognostic value of Ki-67 index, cytology, and growth pattern in mantle-cell lymphoma

In Recent Clinical News

MIPI-b (Biological)

Clinical Risk Band

When to Use

When to Use

How it Works

Variables (Standard MIPI)

The Ki-67 Biological Modifier (MIPI-b)

Clinical Pearls

Clinical Implications

The Evidence

Key Reference

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

Prognostic value of Ki-67 index, cytology, and growth pattern in mantle-cell lymphoma

In Recent Clinical News